1 September 2024
VivaGel phase 3 study results - Investor conference calls
Melbourne Australia: Starpharma Holdings Limited (ASX: SPL, OTCQX SPHRY) will be hosting investor conference calls to discuss results of the Company’s phase 3 clinical trial for the treatment of bacterial vaginosis. The calls will be hosted by Starpharma Chief Executive Officer Dr Jackie Fairley.
To accommodate Starpharma’s international investor base the Company will be holding two conference calls:
Conference call 1 (European and Asian investors): Wednesday 28th November at 8.30pm EDT (United Kingdom 9.30am Wednesday 28th November; Singapore/Hong Kong 5.30pm Wednesday 28th November). Conference ID 75319844 - This will need to be quoted when joining the call.
Conference call 2 (Australian and US investors): Thursday 29th November at 9.15am EDT (United States 5.15pm EST / 2.15pm PST). Conference ID 75320192 - This will need to be quoted when joining the call.
Dial in details:
Australian Participant Dial-In Numbers
02 8314 8370 or Toll-free: 1800 123 296
International Participant Dial In Numbers
These numbers are toll-free dial in numbers for each country listed below. For countries not listed below, the Australian Toll number (+61 2 8314 8370) can be dialed.
China 4001203085
Hong Kong 800 908 865
India 180030106141
Japan 0120 985 190
New Zealand 0800 452 782
Singapore 800 616 2288
United Kingdom 0808 234 0757
United States 1855 293 1544
Download ASX Announcement: VivaGel Phase 3 study results investor calls ( pdf file, 80kb)